[Stereotactic radiotherapy for multiple brain metastases].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Xia HS;Xia HS; Han SY; Li P; Liu ZC; Tang PY
  • Source:
    Ai zheng = Aizheng = Chinese journal of cancer [Ai Zheng] 2005 Jun; Vol. 24 (6), pp. 711-3.
  • Publication Type:
    English Abstract; Journal Article
  • Language:
    Chinese
  • Additional Information
    • Source:
      Publisher: Zhongshan da xue zhong liu fang zhi zhong xin Country of Publication: China NLM ID: 9424852 Publication Model: Print Cited Medium: Print NLM ISO Abbreviation: Ai Zheng Subsets: MEDLINE
    • Publication Information:
      Manufacture: <2009- > : Guangzhou : Zhongshan da xue zhong liu fang zhi zhong xin
      Original Publication: Guangzhou : Zhongshan yi ke da xue Fu shu zhong liu yi yuan
    • Subject Terms:
      Brain Neoplasms/*secondary ; Brain Neoplasms/*surgery ; Lung Neoplasms/*pathology ; Radiosurgery/*methods; Adult ; Aged ; Aged, 80 and over ; Brain Edema/etiology ; Breast Neoplasms/pathology ; Carcinoma, Non-Small-Cell Lung/secondary ; Carcinoma, Non-Small-Cell Lung/surgery ; Carcinoma, Small Cell/secondary ; Carcinoma, Small Cell/surgery ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Radiosurgery/adverse effects ; Retrospective Studies ; Survival Rate
    • Abstract:
      Background & Objective: Stereotactic radiotherapy (SRT) has obvious advantages in treating intracranial tumors, but there are few reports about application of SRT to multiple intracranial tumors. This paper summarized the therapy outcome of patients with multiple brain metastases, and evaluated the efficacy and application of SRT.
      Methods: Clinical data of 136 patients with multiple brain metastases received radiotherapy from Jun. 1996 to Dec. 2002 were reviewed. Of the 136 patients, 52(38.2%) received conventional radiotherapy alone (CR group), 84(61.8%) received SRT or SRT plus whole brain radiotherapy (SRT group).
      Results: Clinical effective rate, and elimination rate of brain metastases (diameter of > 20 mm) were significantly higher in SRT group than in CR group (96.4% vs. 86.5%, P=0.02; 70.4% vs. 36.0%, P=0.007). Persistent brain edema rate was 8.3% in SRT group, and 9.6% in CR group (P=0.767). Intracranial tumor recurrence rate was 25.0% in SRT group, and 19.4% in CR group (P=0.653). Median survival time was significantly longer in SRT group than in CR group (10.5 months vs. 6.5 months, P=0.014); 1-year survival rate was significantly higher in SRT group than in CR group (40.5% vs. 21.2%, P=0.023).
      Conclusion: Reasonable application of SRT could improve life quality and treatment outcome of patients with multiple brain metastases, reduce intracranial tumor recurrence and radiation damage, and prolong patients'survival time.
    • Publication Date:
      Date Created: 20050611 Date Completed: 20070313 Latest Revision: 20150313
    • Publication Date:
      20221213
    • Accession Number:
      15946485